RICE ASTARINA, - (2025) ANALISIS EFEKTIVITAS BIAYA TERAPI ANTIDIABETES KOMBINASI METFORMIN DAN INSULIN DENGAN METFORMIN DAN VILDAGLIPTIN PADA PASIEN T2DM DI INSTALASI RAWAT JALAN RSUD BANDUNG KIWARI. Skripsi thesis, Sekolah Tinggi Farmasi Indonesia.
![[img]](http://repository.stfi.ac.id/style/images/fileicons/text.png) |
Text
S_PSSF_A233022_Title.pdf Download (477kB) |
|
Text
S_PSSF_A233022_Chapter1.pdf Restricted to Repository staff only Download (144kB) |
|
Text
S_PSSF_A233022_Chapter2.pdf Restricted to Repository staff only Download (1MB) |
|
Text
S_PSSF_A233022_Chapter3.pdf Restricted to Repository staff only Download (335kB) |
|
Text
S_PSSF_A233022_Chapter4.pdf Restricted to Repository staff only Download (701kB) |
|
Text
S_PSSF_A233022_Chapter5.pdf Restricted to Repository staff only Download (10kB) |
|
Text
S_PSSF_A233022_Appendix.pdf Restricted to Repository staff only Download (1MB) |
Abstract
Pembiayaan kesehatan di Indoensia semakin tinggi, maka diperlukan analisis efektivitas biaya untuk memilih obat yang efektif secara manfaat dan biaya. Tujuan penelitian untuk menganalisis efektivitas biaya dari dua kombinasi terapi yaitu metformin dan insulin dengan metformin dan vildagliptin pada pasien Diabetes Melitus Tipe 2 (T2DM) di RSUD Bandung Kiwari. Metodologi penelitian secara retrospektif terhadap data rekam medik. Data yang diperoleh diolah dan dianalisis menggunakan aplikasi SPSS dengan uji parametrik yaitu uji independent t-test. Efektivitas pengobatan diukur berdasarkan penurunan nilai HbA1c pasien terhadap nilai pemeriksaan awal. Hasil penelitian, efektivitas rata-rata terapi kombinasi metformin dan insulin adalah 2.02 %, metformin dan vildagliptin adalah 0.92 %. Rata-rata total biaya metformin dan insulin sebesar Rp 4.621.621,- metformin dan vildagliptin Rp 3.245.280,-. Perbandingan efektivitas penggunaan metformin dan insulin dengan metformin dan vildagliptin terhadap profil glikemik HbA1c yaitu 0, 124 (p > 0, 05), artinya tidak terdapat perbedaan signifikan terhadap profil glikemik pada kedua kelompok terapi. Analisis farmakoekonomi dengan metode Cost Effectiveness Analysis (CEA). Hasilnya, kelompok metformin dan insulin lebih cost effective dengan nilai ACER sebesar Rp 2.287.753,- dibandingkan dengan dengan metformin dan vildagliptin sebesar Rp 3.366.473,-. Perhitungan nilai ICER didapatkan sebesar Rp 1.298.095,-. ----- Healthcare costs in Indonesia are increasing, so it's important to analyze the costeffectiveness of treatments to choose medicines that offer the best value in terms of benefits and cost. The purpose of this study was to analyze the cost-effectiveness of two treatment combinations—metformin and insulin, and metformin and vildagliptin—for patients with Type 2 Diabetes Mellitus (T2DM) at RSUD Bandung Kiwari. The research method used a retrospective analysis of medical records. The data was processed and analyzed using SPSS with a parametric test called the independent t-test. The effectiveness of the treatment was measured by the decrease in HbA1c levels compared to initial test results. The study found that the average effectiveness of the combination of metformin and insulin was 2.02%, while the combination of metformin and vildagliptin was 0.92%. The average total cost for metformin and insulin was Rp 4,621,621, while for metformin and vildagliptin it was Rp 3,245,280. The comparison of effectiveness between the two treatment groups in terms of HbA1c profiles showed a value of 0.124 (p > 0.05), which means there was no significant difference in glucose profiles between the two treatment groups. The pharmacoeconomic analysis used the Cost Effectiveness Analysis (CEA) method. The results showed that the group receiving metformin and insulin was more cost-effective, with an ACER value of Rp 2,287,753, compared to metformin and vildagliptin, which had an ACER value of Rp 3,366,473. The ICER calculation resulted in a value of Rp 1,298,095.
| Item Type: | Thesis (Skripsi) |
|---|---|
| Uncontrolled Keywords: | ACER, analisis farmakoekonomi, diabetes melitus, metformin insulin, metformin vildagliptin. ----- ACER, pharmacoeconomic analysis, diabetes mellitus, metformin insulin, metformin vildagliptin. |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine |
| Divisions: | Program Studi S1 Farmasi |
| Depositing User: | pustakawan - - |
| Date Deposited: | 06 Sep 2025 01:44 |
| Last Modified: | 06 Sep 2025 01:44 |
| URI: | http://repository.stfi.ac.id/id/eprint/2769 |
Actions (login required)
 |
View Item |
